ARID1A与PIK3CA突变在卵巢子宫内膜异位症恶变中的研究进展

doi:10.12280/gjfckx.20240878

国际妇产科学杂志 ›› 2025, Vol. 52 ›› Issue (1): 19-22.doi: 10.12280/gjfckx.20240878

ARID1A与PIK3CA突变在卵巢子宫内膜异位症恶变中的研究进展

张云凤, 张宛玥, 卢悦, 王阳阳, 井佳雨, 牟婧祎, 王悦^△()

450003 郑州大学人民医院，河南省人民医院妇产科（张云凤，张宛玥，王阳阳，井佳雨，牟婧祎，王悦）；河南大学人民医院妇产科（卢悦）

收稿日期:2024-09-25 出版日期:2025-02-15 发布日期:2025-02-14
通讯作者: 王悦，E-mail：wangyue0601@163.com
作者简介:^△审校者
基金资助:
国家自然科学基金(82072883);河南省重点研发专项(231111521100)

Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis

ZHANG Yun-feng, ZHANG Wan-yue, LU Yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue()

Department of Obstetrics and Gynecology, Zhengzhou University People′s Hospital, Henan Provincial People′s Hospital, Zhengzhou 450003, China (ZHANG Yun-feng, ZHANG Wan-yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue); Department of Obstetrics and Gynecology, Henan University People′s Hospital, Zhengzhou 450003, China (LU Yue)

Received:2024-09-25 Published:2025-02-15 Online:2025-02-14
Contact: WANG Yue, E-mail: wangyue0601@163.com

摘要/Abstract

摘要：

子宫内膜异位症是一种常见的妇科疾病，育龄期女性的发病率为6%~10%。虽然子宫内膜异位症在形态学上呈良性表现，但易发生种植、侵袭及远处转移。卵巢子宫内膜异位症是最常见的子宫内膜异位症之一，治疗后易复发，严重威胁女性生殖健康。近年来大量研究发现，卵巢子宫内膜异位症具有恶变为卵巢癌的潜力。卵巢子宫内膜异位症恶变过程中最常见的是AT丰富结合域1A（AT-rich interaction domain 1A，ARID1A）与磷脂酰肌醇3激酶催化亚单位α（phosphatidylinositol 3-kinase catalytic subunit alpha，PIK3CA）基因突变，且发生在恶变早期。综述了ARID1A与PIK3CA突变在卵巢子宫内膜异位症恶变中的研究现状。

关键词: 子宫内膜异位症, 卵巢肿瘤, 基因, 突变, ARID1A, PIK3CA

Abstract:

Endometriosis (EMs) is a common gynecological disease with a prevalence of 6% to 10% in women of reproductive age. Although endometriosis is morphologically benign, it is susceptible to implantation, invasion and distant metastasis. Ovarian endometriosis is one of the most common forms of endometriosis, which is prone to recurrence after treatment and poses a serious threat to female reproductive health. In recent years, a large number of studies have found that ovarian endometriosis has the potential for malignant transformation into ovarian cancer. In the malignant transformation process of ovarian endometriosis, the most common mutations are in the ARID1A and PIK3CA genes, which occur in the early stage of malignancy. The current status of ARID1A and PIK3CA mutations in malignant transformation of ovarian endometriosis is reviewed.

Key words: Endometriosis, Ovarian neoplasms, Genes, Mutation, ARID1A, PIK3CA

张云凤, 张宛玥, 卢悦, 王阳阳, 井佳雨, 牟婧祎, 王悦. ARID1A与PIK3CA突变在卵巢子宫内膜异位症恶变中的研究进展[J]. 国际妇产科学杂志, 2025, 52(1): 19-22.

ZHANG Yun-feng, ZHANG Wan-yue, LU Yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue. Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 19-22.

参考文献 28

[1]	Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis[J]. BMJ, 2022,379:e070750. doi: 10.1136/bmj-2022-070750.
[2]	Guidozzi F. Endometriosis-associated cancer[J]. Climacteric, 2021, 24(6):587-592. doi: 10.1080/13697137.2021.1948994.
[3]	郎景和. 子宫内膜异位症和肿瘤兼论子宫内膜异位症恶变[J]. 中华妇产科杂志, 2019, 54(9):577-581. doi: 10.3760/cma.j.issn.0529-567x.2019.09.001.
[4]	Odnokoz O, Wavelet-Vermuse C, Hophan SL, et al. ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics[J]. Epigenomics, 2021, 13(10):809-823. doi: 10.2217/epi-2020-0414. pmid: 33890484
[5]	Zhang X, Zhang Y, Zhao J, et al. ARID1A mutations in cancer development: mechanism and therapy[J]. Carcinogenesis, 2023, 44(3):197-208. doi: 10.1093/carcin/bgad011. pmid: 36882165
[6]	Lu S, Duan R, Cong L, et al. The effects of ARID1A mutation in gastric cancer and its significance for treatment[J]. Cancer Cell Int, 2023, 23(1):296. doi: 10.1186/s12935-023-03154-8. pmid: 38008753
[7]	Peerapen P, Sueksakit K, Boonmark W, et al. ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An in vitro cellular mechanism study[J]. J Cancer, 2022, 13(2):373-384. doi: 10.7150/jca.65511.
[8]	Mullen J, Kato S, Sicklick JK, et al. Targeting ARID1A mutations in cancer[J]. Cancer Treat Rev, 2021,100:102287. doi: 10.1016/j.ctrv.2021.102287.
[9]	Steinbuch SC, Lüß AM, Eltrop S, et al. Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance[J]. Int J Mol Sci, 2024, 25(8):4306. doi: 10.3390/ijms25084306.
[10]	Driva TS, Schatz C, Haybaeck J. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis[J]. Biomolecules, 2023, 13(8):1253. doi: 10.3390/biom13081253.
[11]	Liu G, Xu P, Fu Z, et al. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis[J]. J Cell Biochem, 2017, 118(12):4517-4525. doi: 10.1002/jcb.26109. pmid: 28466574
[12]	Heckl M, Schmoeckel E, Hertlein L, et al. The ARID1A, p53 and β-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium[J]. PLoS One, 2018, 13(2):e0192881. doi: 10.1371/journal.pone.0192881.
[13]	Peng Y, Wang Y, Zhou C, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?[J]. Front Oncol, 2022,12:819128. doi: 10.3389/fonc.2022.819128.
[14]	Mishra R, Patel H, Alanazi S, et al. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects[J]. Int J Mol Sci, 2021, 22(7):3464. doi: 10.3390/ijms22073464.
[15]	Madsen RR, Semple RK. PIK3CA-related overgrowth: silver bullets from the cancer arsenal?[J]. Trends Mol Med, 2022, 28(4):255-257. doi: 10.1016/j.molmed.2022.02.009. pmid: 35272946
[16]	Montoro-Jiménez I, Granda-Díaz R, Menéndez ST, et al. Combined PIK3CA and SOX2 Gene Amplification Predicts Laryngeal Cancer Risk beyond Histopathological Grading[J]. Int J Mol Sci, 2024, 25(5):2695. doi: 10.3390/ijms25052695.
[17]	Tan ES, Fan W, Knepper TC, et al. Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer[J]. Target Oncol, 2022, 17(4):483-492. doi: 10.1007/s11523-022-00898-7. pmid: 35767139
[18]	Shi Q, Xuhong J, Tian H, et al. Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(1): 188847. doi: 10.1016/j.bbcan.2022.188847.
[19]	Choi JH, Yu J, Jung M, et al. Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer[J]. Medicine(Baltimore), 2023, 102(38):e35267. doi: 10.1097/MD.0000000000035267.
[20]	Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma[J]. J Pathol, 2011, 225(2):189-194. doi: 10.1002/path.2940.
[21]	Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma[J]. Virchows Arch, 2012, 460(1):77-87. doi: 10.1007/s00428-011-1169-8.
[22]	Passarelli A, Carbone V, Pignata S, et al. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity[J]. Gynecol Oncol, 2024, 183:61-67. doi: 10.1016/j.ygyno.2024.02.029. pmid: 38518529
[23]	Anabel Sinberger L, Zahavi T, Sonnenblick A, et al. Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer[J]. Sci Rep, 2023, 13(1):20911. doi: 10.1038/s41598-023-48002-x.
[24]	Tharin Z, Richard C, Derangère V, et al. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy[J]. Sci Rep, 2023, 13(1):4467. doi: 10.1038/s41598-023-31593-w. pmid: 36934165
[25]	Sun Y, Liu G. Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?[J]. J Cancer, 2021, 12(22):6773-6786. doi: 10.7150/jca.61107. pmid: 34659566
[26]	Bolton KL, Chen D, Corona de la Fuente R, et al. Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes[J]. Clin Cancer Res, 2022, 28(22):4947-4956. doi: 10.1158/1078-0432.CCR-21-3817. pmid: 35816189
[27]	Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells[J]. Am J Physiol Cell Physiol, 2004, 287(2):C281-C291. doi: 10.1152/ajpcell.00422.2003.
[28]	Chandler RL, Damrauer JS, Raab JR, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling[J]. Nat Commun, 2015,6:6118. doi: 10.1038/ncomms7118.

ARID1A与PIK3CA突变在卵巢子宫内膜异位症恶变中的研究进展

Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹秀蓉, 周文柏, 范香, 王逸斐, 朱鹏峰. 单细胞RNA测序解析子宫内膜异位症血管生成机制[J]. 国际妇产科学杂志, 2025, 52(2): 199-205.
[2]	殷婷, 丛慧芳. 子宫内膜异位症与痛觉敏化的免疫学研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 206-210.
[3]	江爱美, 张信美. 腹壁子宫内膜异位症的治疗进展[J]. 国际妇产科学杂志, 2025, 52(2): 211-216.
[4]	白耀俊, 王思瑶, 令菲菲, 张森淮, 李红丽, 刘畅. Trop-2及靶向Trop-2抗体偶联药物在妇科恶性肿瘤中的应用进展[J]. 国际妇产科学杂志, 2025, 52(1): 1-7.
[5]	李楠, 彭二玄, 刘风花. 卵巢上皮性癌脑转移20例临床分析[J]. 国际妇产科学杂志, 2025, 52(1): 23-27.
[6]	贾炎峰, 吴珍珍, 王维红, 王玥元, 李娟. 原发性卵巢腺鳞癌一例[J]. 国际妇产科学杂志, 2025, 52(1): 32-36.
[7]	宋丽芳, 吴珍珍, 毛宝宏, 赵小丽, 刘青. 卵巢癌腹股沟淋巴结孤立转移一例[J]. 国际妇产科学杂志, 2025, 52(1): 37-41.
[8]	石百超, 王宇, 常惠, 卢凤娟, 关木馨, 余健楠, 吴效科. 中药及天然产物改善子宫内膜异位症的作用机制[J]. 国际妇产科学杂志, 2025, 52(1): 66-71.
[9]	邱婉宁, 魏瑗. 单卵双胎妊娠不一致异常的病因学研究进展[J]. 国际妇产科学杂志, 2024, 51(6): 607-610.
[10]	刘思敏, 李红丽, 郭希, 胡雅莉, 杨永秀. 妊娠晚期合并卵巢浆液性囊腺瘤蒂扭转一例[J]. 国际妇产科学杂志, 2024, 51(6): 632-635.
[11]	陈星羽, 韦雅婧, 梁炎春. 基于基因组学图谱构建的子宫平滑肌肉瘤前沿进展[J]. 国际妇产科学杂志, 2024, 51(6): 641-647.
[12]	郭希, 刘思敏, 魏佳, 杨永秀. 卵巢及输卵管子宫内膜异位症恶变为透明细胞癌一例[J]. 国际妇产科学杂志, 2024, 51(6): 680-683.
[13]	高明周, 高冬梅, 马凤君, 张轲鑫, 张浩. 从雌激素波动视角探讨经前烦躁障碍症抑郁-疼痛发生基础研究进展[J]. 国际妇产科学杂志, 2024, 51(6): 703-706.
[14]	张艳, 张意茗. 子宫腺肌病合并卵巢子宫内膜异位囊肿取卵术后并发盆腔脓肿一例[J]. 国际妇产科学杂志, 2024, 51(6): 717-720.
[15]	李慧敏, 胡雅莉, 张森淮, 马晓梅, 许飞雪. 高强度聚焦超声技术在妇产科疾病中的应用进展[J]. 国际妇产科学杂志, 2024, 51(5): 486-491.